Guardian Capital LP purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, HoldingsChannel.com reports. The fund purchased 6,677 shares of the biopharmaceutical company’s stock, valued at approximately $541,000.
A number of other hedge funds have also added to or reduced their stakes in GILD. Welch Investments LLC acquired a new stake in Gilead Sciences during the 3rd quarter valued at $108,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the 3rd quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences during the 2nd quarter valued at $147,000. Hanson & Doremus Investment Management increased its holdings in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Rowland & Co. Investment Counsel ADV acquired a new stake in Gilead Sciences during the 2nd quarter valued at $153,000. 75.84% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $78.22 on Friday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.56. The stock has a market capitalization of $108,106.83, a price-to-earnings ratio of 22.48, a PEG ratio of -1.83 and a beta of 1.22.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
GILD has been the topic of a number of recent research reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a research report on Friday, October 13th. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets decreased their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Maxim Group set a $94.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $86.56.
In other news, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 578,333 shares of company stock worth $44,100,508 over the last 90 days. 1.30% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://sportsperspectives.com/2018/02/09/guardian-capital-lp-invests-541000-in-gilead-sciences-inc-gild-stock.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.